statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 PR Newswire PITTSBURGH, April 16, 2024 PITTSBURGH, April...

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024

Viatris Appoints Corinne Le Goff as Chief Commercial Officer Viatris Appoints Corinne Le Goff as Chief Commercial Officer PR Newswire PITTSBURGH, April 15, 2024 PITTSBURGH, April 15, 2024...

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

Understanding the Barriers to Outperformance for Viatris IncRelated Stocks: VTRS...

Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment...

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl  (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Viatris announces U.S. commercial launch of Ryzumvi

Viatris Announces the Launch of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% in the United States Viatris Announces the Launch of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% in the United...

Viatris Announces the Launch of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% in the United States

Teva and Viatris revives chance to dispute J&J's schizophrenia drug patent...

Teva and Viatris revives chance to dispute J&J's schizophrenia drug patent

Viatris Stock Is Still Worth Buying

A month has gone by since the last earnings report for Viatris (VTRS). Shares have lost about 3.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up...

Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Volume	5.84M
52-Wk High	$13.62
52-Wk Low	$8.74

VTRS Viatris Inc

About

Feed

News

Sentiment

Earnings

Fundamentals